Akido Labs – an AI and care delivery company reimagining healthcare – announced it has raised $60 million in Series B funding. The funding round was led by Oak HC/FT with participation from Greco, SNR, and existing investors Y Combinator, Future Communities Capital, Jeff Dean (Chief Scientist, Google DeepMind & Google Research), and the Comprehensive Blood & Cancer Center.
What the funding will be used for: The funding will expand the reach of ScopeAI, a system that increases clinical capacity and improves healthcare access.
ScopeAI transforms how Akido providers practice medicine, enabling them to care for dramatically more patients without compromising on quality. This frees up providers’ time to focus on complex cases while increasing the total number of patients the system can support.
With this new funding, Akido will advance the development and deployment of ScopeAI throughout its Akido Care medical network of 240 providers across 26 specialties. It will also help support Akido’s entrance into new markets, like the recently announced first-of-its-kind healthcare program in New York City designed to address specific chronic diseases for professional rideshare and for-hire drivers.
Value proposition: The U.S. requires 3+ billion doctor visits annually, but only 825 million are available. Due to high demand for doctor visits, there are longer wait times, especially for specialists, leading to rushed appointments and rising rates of preventable disease. And Akido is addressing this crisis by embedding medical intelligence directly into the clinical workflow, bringing scale, efficiency, and consistency to the front lines of care.
With a ScopeAI visit, a trained Medical Assistant (MA) meets with a patient, guided by intelligent prompts from ScopeAI throughout the encounter. ScopeAI uses clinical reasoning to actively listen, adapt in real time, and build a comprehensive understanding of the patient’s condition.
And its scribing and auditory capabilities enable dynamic conversation while simultaneously generating a full clinical report, including a preliminary diagnosis, treatment plan, and justification log for each decision it makes. Through ScopeAI, providers gain a deeper, more complete picture of a patient’s health with less time spent capturing it. And an Akido provider can oversee a team of MAs conducting ScopeAI visits, increasing access to care while enabling the provider to focus on higher-acuity or more complex cases.
Akido’s AI-based healthcare visits have delivered 5 times more face-to-face time with patients.
Akido was launched in 2015 to reimagine healthcare for historically vulnerable communities by utilizing AI/ML. And in 2022, Akido launched the aforementioned Akido Care service, a medical network that today includes nearly 100 clinics, offering primary and specialty care across 26 sub-specialties.
This dual strategy allowed Akido to launch ScopeAI by utilizing its proprietary dataset of over 10 million patient case studies and a reinforcement-loop-human-feedback (RLHF) environment. ScopeAI is one of the most sophisticated clinical AI systems available to providers, and it is continuously refined by incorporating real-time provider feedback.
By integrating ScopeAI into the Akido Care medical network, Akido is prepared to empower providers to deliver highly personalized care to individual patients while scaling programs at a population level.
KEY QUOTES:
“We built ScopeAI to tackle the single biggest challenge facing healthcare systems worldwide: the physician shortage. With demand for care far exceeding supply, AI is the key to addressing the global doctor deficit, empowering healthcare providers, and ensuring patients receive the timely, high-quality care they deserve, regardless of financial means or geography. At Akido, we believe exceptional healthcare is a basic human right. Our work has always focused on democratizing high quality healthcare, and this funding enables us to accelerate that mission.”
Prashant Samant, Co-Founder & CEO of Akido
“Akido is delivering on the promise of changing how patients experience a visit with their provider through AI. With its robust, longitudinal dataset, Akido has the refinement in its foundational model to offer clinical accuracy where others have struggled. We are excited to partner with their exceptional team of healthcare and technical operators to scale ScopeAI, expanding access to high-quality, AI-powered care for more patients.”
Andrew Adams, Co-Founder & Managing Partner at Oak HC/FT
